Drugs News and Research

RSS

NanoSmart receives USPTO Notice of Allowance for cancer tumor targeting technology

NanoSmart™ Pharmaceuticals, Inc., a California corporation developing novel biopharmaceuticals, is pleased to report that it has received a Notice of Allowance for a US patent on its proprietary cancer tumor targeting technology.

16 Aug 2010

Amphetamine abuse associated with increased risk of aortic dissection

Young adults who abuse amphetamines may be at greater risk of suffering a tear in the main artery leading from the heart, UT Southwestern Medical Center researchers have found.

16 Aug 2010

Study reveals how galectin-3 carbohydrate-binding protein promotes angiogenesis

A new study describes how a carbohydrate-binding protein, galectin-3, promotes angiogenesis, the growth of new blood vessels. Targeting the protein, scientists identified two approaches that significantly reduced angiogenesis in mice. These discoveries, published online August 16 in The Journal of Experimental Medicine, may lead to novel treatments for diseases caused by excessive angiogenesis, including age-related macular degeneration, cancer, and diabetes.

16 Aug 2010

Politics and Health Reform: Democrats, Republicans trying to sway seniors

The Associated Press: Democrats, "running scared in an election year," are hopeful that a $250 check - to help seniors afford prescription drugs - will turn the tide of public opinion. "Democrats ... are trying to overcome older people's mistrust of the new health care law, which expands coverage for younger generations by cutting Medicare payments to hospitals and insurers. … Behind the hoopla, the reality is modest. The $250 check, for example, is just a fraction of what many people in the prescription coverage gap have to pay.

16 Aug 2010

Lotus Pharmaceuticals second-quarter net income increases 32% to $6.3 million

Lotus Pharmaceuticals, Inc., a growing developer, manufacturer and seller of medicine and drugs in the People's Republic of China, reported today its financial results for the quarter and six months ended June 30, 2010.

16 Aug 2010

NanoViricides' anti-Herpes drug candidates demonstrate significant efficacy in cell culture studies

NanoViricides, Inc., reports that its anti-Herpes drug candidates demonstrated significant efficacy in the recently completed cell culture studies. The studies were performed in the laboratory of Dr. Ken Rosenthal at Northeastern Ohio Universities Colleges of Medicine and Pharmacy.

16 Aug 2010

China Jo-Jo Drugstores reports highest first quarter revenues, gross profit and operating income to date

China Jo-Jo Drugstores, Inc.("Jo-Jo Drugstores" or the "Company"), which operates a retail pharmacy chain in the People's Republic of China (the "PRC"), today reported its financial results for the fiscal quarter ended June 30, 2010.

16 Aug 2010

KemPharm receives patent for LAT prodrug technology for Attention Deficit – Hyperactivity Disorder treatment

KemPharm, Inc. announced today that it has received a Notice of Issuance from the United States Patent and Trademark Office (USPTO) for its patent application entitled "Polar Hydrophilic Prodrugs of Amphetamine and Other Stimulants and Processes for Making and Using the Same", U.S. Patent No. 7,772,222. This patent protects broad aspects of the Company's core Ligand Activated Therapy (LAT) prodrug technology platform and its application to the treatment of Attention Deficit – Hyperactivity Disorder.

16 Aug 2010

International community must approach cancer as a global health priority

Once thought to be a problem primarily in the developed world, cancer is now a leading cause of death and disability in poorer countries. Almost two-thirds of the 7.6 million cancer deaths in the world occur in low- and middle-income countries.

16 Aug 2010

Survey: Majority of U.S. pharmaceutical companies develop drugs for mental illness

Pharmaceutical research and biotechnology companies in New Jersey, California, New York and North Carolina are responsible for 192 of the 313 medicines in development today to treat mental illnesses, a new survey shows.

16 Aug 2010

Clinical trials activity of Synexus in Hungary increases 25% in first-half of 2010

Synexus clinical trials activity in Hungary has increased by 25% during the first half of 2010. The company's Dedicated Research Centre has been operating in Hungary since 2006 and has become one of the company's most successful CEE sites. The Budapest-based operation has been involved in excess of 74 trials since being acquired by Synexus, and randomized over 600 patients.

From AES - Accelerated Enrollment Solutions 16 Aug 2010

Delegates explore agricultural cooperation, expanded ties at two-day China-Africa Agricultural Forum

Chinese and African officials concluded the China-Africa Agricultural Forum in Beijing on Thursday, which explored possibilities for agricultural cooperation and addressed food security issues, Xinhua reports.

16 Aug 2010

MeCP2 protein regulates properties of psychostimulant drugs: Research

When a certain protein is mutated or missing, symptoms of the neurodevelopmental disorder Rett syndrome arise, causing a gradual loss of brain function during early development.This fact led Duke University Medical Center researchers to test a theory that the protein might also contribute to nerve-cell connection (synapse) changes in a fully formed adult mouse brain when exposed to psychostimulant use.

16 Aug 2010

Nymox second-quarter net loss increases to $1.75 million

Nymox Pharmaceutical Corporation announced today its financial results for the second quarter of 2010. Nymox reported a net loss of $1,745,798, or $0.05 per share for the quarter and $3,015,348, or $0.10 per share for the six months ending June 30, 2010, compared to $1,220,152, or $0.04 per share for the quarter and $2,224,411, or $0.07 per share for the six months ending June 30, 2009. Net losses include stock compensation charges for the quarter of $245,245 in 2010 and $248,886 in 2009 and for the six months ending June 30 of $440,465 in 2010 and $558,536 in 2009.

16 Aug 2010

New T cell engineering approach can improve success rate of immune-cell therapies

Clinical trials using patients' own immune cells to target tumors have yielded promising results. However, this approach usually works only if the patients also receive large doses of drugs designed to help immune cells multiply rapidly, and those drugs have life-threatening side effects. Now a team of MIT engineers has devised a way to deliver the necessary drugs by smuggling them on the backs of the cells sent in to fight the tumor. That way, the drugs reach only their intended targets, greatly reducing the risk to the patient.

16 Aug 2010

Research Roundup: Disabled Medicare Enrollees' challenges; Increasing ER visits; costs/benefits of Part D

Health Affairs: Medicare Doesn't Work As Well For Younger, Disabled Beneficiaries As It Does For Older Enrollees - This paper examines "how well Medicare works for [the 8 million] nonelderly disabled beneficiaries compared to the elderly, based on findings from a nationally representative survey of noninstitutionalized Medicare beneficiaries conducted in 2008 by the Kaiser Family Foundation."

16 Aug 2010

U.S. officials probing payments by drug and device makers to doctors overseas

The New York Times reports that federal officials are investigating whether a dozen drug and device makers "made illegal payments to doctors and health officials in foreign countries." Although pharmaceutical companies routinely contract with doctors in the United States to be consultants, experts say the situation is more complex overseas because "in much of the rest of the world, doctors are government employees. And even consulting arrangements that would be considered routine in the United States might violate the Foreign Corrupt Practices Act, particularly if the payments are outsize or the arrangements are not disclosed to the governments.

16 Aug 2010

Researchers develop screening tool to observe nanoparticle reaction inside the body

Researchers at North Carolina State University have developed a method for predicting the ways nanoparticles will interact with biological systems - including the human body. Their work could have implications for improved human and environmental safety in the handling of nanomaterials, as well as applications for drug delivery.

16 Aug 2010

Scientists discover new signaling pathway to reduce tumour growth in glioblastoma multiforme

Malignant gliomas are the most common subtype of primary brain tumor - and one of the deadliest. Even as doctors make steady progress treating other types of solid tumor cancers, from breast to prostate, the most aggressive form of malignant glioma, called a glioblastoma multiforme or GBM, has steadfastly defied advances in neurosurgery, radiation therapy and various conventional or novel drugs. But an international team of scientists, headed by researchers at the Ludwig Institute for Cancer Research (LICR) at the University of California, San Diego School of Medicine, reports in the August 15 issue of Genes & Development that they have discovered a new signaling pathway between GBM cells - one that, if ultimately blocked or disrupted, could significantly slow or reduce tumor growth and malignancy.

16 Aug 2010

Daily dose of aspirin may reduce prostate cancer risk: US Study

A US study has found that a daily dose of aspirin may reduce the risk of prostate cancer, but Cancer Research UK has noted that regular use of aspirin can cause serious side-effects and should not be undertaken unless recommended by a doctor.Several previous studies have looked at the possibility of an association between aspirin use and a reduced risk of prostate cancer.In the latest study, scientists at the Fred Hutchinson Cancer Research Centre in Seattle, led by Dr Janet Stanford, looked at data on 1,001 prostate cancer patients and a similar number of cancer-free volunteers.

16 Aug 2010

Drugs News and Research

NanoSmart receives USPTO Notice of Allowance for cancer tumor targeting technology

Amphetamine abuse associated with increased risk of aortic dissection

Study reveals how galectin-3 carbohydrate-binding protein promotes angiogenesis

Politics and Health Reform: Democrats, Republicans trying to sway seniors

Lotus Pharmaceuticals second-quarter net income increases 32% to $6.3 million

NanoViricides' anti-Herpes drug candidates demonstrate significant efficacy in cell culture studies

China Jo-Jo Drugstores reports highest first quarter revenues, gross profit and operating income to date

KemPharm receives patent for LAT prodrug technology for Attention Deficit – Hyperactivity Disorder treatment

International community must approach cancer as a global health priority

Survey: Majority of U.S. pharmaceutical companies develop drugs for mental illness

Clinical trials activity of Synexus in Hungary increases 25% in first-half of 2010

Delegates explore agricultural cooperation, expanded ties at two-day China-Africa Agricultural Forum

MeCP2 protein regulates properties of psychostimulant drugs: Research

Nymox second-quarter net loss increases to $1.75 million

New T cell engineering approach can improve success rate of immune-cell therapies

Research Roundup: Disabled Medicare Enrollees' challenges; Increasing ER visits; costs/benefits of Part D

U.S. officials probing payments by drug and device makers to doctors overseas

Researchers develop screening tool to observe nanoparticle reaction inside the body

Scientists discover new signaling pathway to reduce tumour growth in glioblastoma multiforme

Daily dose of aspirin may reduce prostate cancer risk: US Study

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News